Document is current

Any future updates will be listed below

Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

Crossref DOI link: https://doi.org/10.1038/s41392-025-02337-1

Published Online: 2025-07-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark